Detalhe da pesquisa
1.
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting ß2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Lancet
; 388(10039): 31-44, 2016 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27130691
2.
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.
JAMA
; 315(5): 469-79, 2016 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26836729
3.
Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
Rheumatology (Oxford)
; 52(7): 1285-92, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23485476
4.
Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
J Rheumatol
; 41(8): 1703-11, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25028379
5.
Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.
Arthritis Res Ther
; 15(1): R25, 2013 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23375025
6.
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Arthritis Care Res (Hoboken)
; 64(10): 1462-70, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22549879